Alexi Tallan
Biochemistry, Genetics and Molecular Biology · The Ohio State University
Publications
15
Citations
29
Est. group size
~3
Recurring co-author estimate
Active years
8
Publishing since 2019
Alexi Tallan studies how proteins interact with DNA and chromatin (the packaged form of DNA in cells) to control gene activity, with a particular focus on the fusion protein PAX3::FOXO1, which is implicated in rhabdomyosarcoma, a type of cancer that arises in muscle tissue. The work combines biochemistry and epigenomics techniques, including tools that can artificially degrade specific proteins to study how genome structure is organized. This research aims to understand the molecular mechanisms underlying cancer-associated gene regulation.
Publication output was low or absent in the earlier part of the decade but has increased notably since 2023, suggesting a growing pace of research activity in recent years.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Abstract B016: Biochemical mechanisms of PAX3::FOXO1 chromatin invasion in Rhabdomyosarcoma
Cancer Research · 2026
- Functional Epigenomics: Pioneering Changes in Chromatin Structure
Biochemistry · 2023
- Inducible Protein Degradation to Understand Genome Architecture
Biochemistry · 2021
- Cancer Research×5
- bioRxiv (Cold Spring Harbor Laboratory)×3
- Toxicological Sciences×2
- Biochemistry×2
- Future Virology×1
- Benjamin D. Sunkel
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Benjamin Z. Stanton
Biochemistry, Genetics and Molecular Biology · The Ohio State University
- Sungyun Kang
Biochemistry, Genetics and Molecular Biology · Indiana University
- Phillip Wyss
Biochemistry, Genetics and Molecular Biology · Purdue University West Lafayette
- Gabriel E. Zentner
Biochemistry, Genetics and Molecular Biology · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile